This year's comprehensive conference program caters to both adult and pediatric nephrologists, nurses, and Advanced Practice Providers (APPs), offering a diverse range of topics at the intersection of cancer and kidney disease. The presentations will delve into various aspects of onconephrology research, clinical surveillance, and management of immune checkpoint inhibitor (ICI) toxicity, as well as renal implications of cellular therapies such as CAR-T cell therapy. The conference will explore topics such as biomarkers and other serum markers in ICI toxicity, renal outcomes in CAR-T cell therapy, and the use of urinary T-cells in the management of ICI toxicity. Additionally, the program will address hyponatremia and electrolyte emergencies in cancer, methotrexate nephrotoxicity, and the long-term implications of childhood cancer on renal function. Throughout the conference, attendees will benefit from engaging case discussions and Q&A sessions, providing them with ample opportunities to interact with and learn from experts in the field. This dynamic and multidisciplinary approach ensures that the conference will offer something interesting and relevant for all professionals involved in the care of patients with kidney disease and cancer.

Learning Objectives:

Gain insight into the current and future needs in Onconephrology research and their implications for clinical practice.
Identify clinical surveillance and management strategies for Immune Checkpoint Inhibitor (ICI) toxicity, including the utility of urinary T-cells and serum biomarkers.
Analyze the risk of AKI and outcomes in patients with low GFR undergoing CAR-T cell therapy, and the implications of CAR-T cells for kidney transplant recipients.
Recognize the renal complications of thrombotic microangiopathy, graft vs host disease, and cellular therapies in hematopoietic stem cell transplantation.
Discuss trial design for ICI surveillance in solid organ transplant patients and understand the implications of ICI therapy in this population.
Manage electrolyte emergencies in cancer patients, including hyponatremia, and understand their impact on patient outcomes.

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 11.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity will award 11.50 Nursing Contact Hour(s)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

OncoNephrology Symposium 2023

Important Dates!

Accreditation Statement:

Credit Designation:

American Board of Internal Medicine MOC Credit:

Endorsed By:

International Society of Nephrology

Affiliated Organizations:

American Society of Onconephrology - ASON

University of Texas MD Anderson Cancer Center